~~Designation:F641–98a (Reapproved 2003)~~ Designation: F 641 – 09

Standard Specification for Implantable Epoxy Electronic Encapsulants[1]

This standard is issued under the fixed designation F 641; the number immediately following the designation indicates the year of original adoption or, in the case of revision, the year of last revision. A number in parentheses indicates the year of last reapproval. A superscript epsilon (ε) indicates an editorial change since the last revision or reapproval.

1. Scope

1.1 This specification covers thermoset plastics based on diglycidyl ethers of bisphenol A and amino functional curing agents or amine catalysts.

1.2 The epoxy encapsulants covered by this specification are intended to provide a tissue-compatible protective covering for implantable medical devices such as pulse generators, telemetry devices and RF receivers. The biocompatibility of epoxy plastics has not been established. Epoxy plastic is a generic term relating to the class of polymers formed from epoxy resins, certain curing agents or catalysts and various additives. Since many compositions and formulations fall under this category, it is essential that the fabricator assure safety of implantability of the specific composition or formulation for the intended use by current state-of-the-art test methods. This specification can be used as a basis for standardized evaluation of biocompatibility for such implantable encapsulants.

1.3 The encapsulants covered by this specification are for use in devices intended as long-term implants.

1.4 *Limitations*~~— This specification covers only the initial qualification of epoxy encapsulants for implantable electronic circuitry. Some of the requirements are not applicable to routine lot to lot quality control.~~

~~1.5~~*—This specification covers only the initial qualification of epoxy encapsulants for implantable electronic circuitry. Some of the requirements are not applicable to routine lot-to-lot quality control.*

1.5 The values stated in SI units are to be regarded as standard. No other units of measurement are included in this standard.

1.6 *This standard does not purport to address all of the safety concerns, if any, associated with its use. It is the responsibility of the user of this standard to establish appropriate safety and health practices and determine the applicability of regulatory limitations prior to use.*

2. Referenced Documents

2.1 *ASTM Standards:*[2]

D 149 Test Method for Dielectric Breakdown Voltage and Dielectric Strength of Solid Electrical Insulating Materials at Commercial Power Frequencies

D 150 Test Methods for ~~ac~~AC Loss Characteristics and Permittivity (Dielectric Constant) of Solid Electrical ~~Insulating Materials~~[2]Insulation

D 257 Test Methods for ~~dc~~DC Resistance or Conductance of Insulating Materials

D 570 Test Method for Water Absorption of Plastics

D 638 Test Method for Tensile Properties of Plastics

D 790 Test Methods for Flexural Properties of Unreinforced and Reinforced Plastics and Electrical Insulating Materials

~~D883 Terminology Relating to Plastics~~[3] 1042

~~D1042~~ Test Method for Linear Dimensional Changes of Plastics Under Accelerated Service Conditions

D 1239 Test Method for Resistance of Plastic Films to Extraction by Chemicals

D 1434 Test Method for Determining Gas Permeability Characteristics of Plastic Film and Sheeting

~~D1763 Specification for Epoxy Resins~~[3] 2240

~~D1898 Practice for Sampling of Plastics~~

~~D2240~~ Test Method for Rubber Property—Durometer Hardness

D 2471 ~~Test Method~~ Practice for Gel Time and Peak Exothermic Temperature of Reacting Thermosetting Resins

D 2562 Practice for Classifying Visual Defects in Parts Molded from Reinforced Thermosetting Plastics

[1] This specification is under the jurisdiction of ASTM Committee F04 on Medical and Surgical Materials and Devices and is the direct responsibility of Subcommittee F04.11 on Polymeric Materials.

~~Current edition approved Apr. 10, 2003. Published May 2003. Originally approved in 1979. Last previous edition approved in 1998 as F641–98a.~~

Current edition approved Aug. 1, 2009. Published September 2009. Originally approved in 1979. Last previous edition approved in 2003 as F 641 – 98a(2003).

[2] For referenced ASTM standards, visit the ASTM website, www.astm.org, or contact ASTM Customer Service at service@astm.org. For *Annual Book of ASTM Standards* ~~, Vol 10.01.~~volume information, refer to the standard's Document Summary page on the ASTM website.

D 2566 Test Method for Linear Shrinkage of Cured Thermosetting Casting Resins During Cure[3]
D 2734 Test Methods for Void Content of Reinforced Plastics
D 3137 Test Method for Rubber Property—Hydrolytic Stability
F 74 Practice for Determining Hydrolytic Stability of Plastic Encapsulants for Electronic Devices[0]
F 135 Test Method for Embedment Stress Caused by Casting Compounds on Glass-Encased Electronic Components[0]
F 602 Criteria for Implantable Thermoset Epoxy Plastics
F 748 Practice ~~For~~for Selecting Generic Biological Test Methods for Materials and Devices
F 895 Test Method for Agar Diffusion Cell Culture Screening for Cytotoxicity
F 981 Practice for Assessment of Compatibility of Biomaterials for Surgical Implants with Respect to Effect of Materials on Muscle and Bone

2.2 *AAMI Standard:*
~~EOS-D E-O Sterilization Standard~~
EOS-D E-O Sterilization Standard[4]
2.3 *ISO Standard:*
ISO 10993 Biological Evaluation of Medical Devices[5]

3. Classification

3.1 Encapsulants shall be classified as follows:
3.1.1 *Type I*—Those encapsulants which contact the tissue directly or indirectly.
3.1.2 *Type II*—Those encapsulants used only within hermetically sealed containers. The epoxy encapsulant has no contact with tissues or physiological fluids.

4. Chemical Composition

4.1 *Additives* (Type I Encapsulants Only):
4.1.1 *Reactive Diluents*—The following compounds when used as reactive diluents shall not be used in concentrations greater than 12 parts per hundred resin (phr).
4.1.1.1 Butyl glycidyl ether (BGE).
4.1.1.2 Phenyl glycidyl ether (PGE).
4.1.2 *Other Additives (see* Note 1)—Other additives shall be shown to be nonextractable in 37°C physiological saline for the device design life in concentrations sufficient to significantly affect the properties of the encapsulant or to produce a significant biological reaction.

NOTE 1—Other additives, as indicated in Criteria F 602, include compounds such as nonreactive diluents, fillers, release agents, and the like.

4.1.3 *Phthalate Esters*—Phthalate esters such as dibutyl phthalate shall not be used in concentrations ≥10 phr.
4.2 *Mix Ratios* (Type I and Type II Encapsulants):
4.2.1 *Amines*—The mix ratio shall be maintained at ±5 equivalent % of stoichiometry.
4.2.2 *Catalysts*—The mix ratio shall be maintained within the ranges recommended by the formulator.
4.3 *Carbonates (Type I and Type II Encapsulants)*—The encapsulant shall be poured under conditions such that the formation of amine carbonates is minimized. The device manufacturer may specify maximum limits ~~of~~for carbon dioxide or water vapor, or both, in the atmosphere in which the encapsulant is being mixed or poured.

5. Physical Properties

5.1 *Type I Encapsulants*:
5.1.1 *Peak Exotherm Temperature (Test Method D 2471)*—The peak exotherm temperature during cure shall be kept below the maximum acceptable value for the lowest temperature rated component of the device.
5.1.2 *Fully Cured Specimens*—The required properties measured on fully cured specimens conditioned as in 6.1 are as follows:
5.1.2.1 *Transparency*—In cases where no fillers or reinforcements are used, the encapsulant shall have sufficient transparency so that the circuitry may be visually inspected after encapsulation.
5.1.2.2 *Foreign Particles*—No foreign particles, particulate ~~matter and~~matter, or gross contamination shall be observed when checked under 2× wide field magnification.
5.1.2.3 ~~*USP Biological Tests Plastic Containers, Class IV*—Pass.~~
~~5.1.2.4USP Pyrogen Test~~ Biocompatibility Testing—While cell culture methods as described in Test Method F 895 may be appropriate for the lot-to-lot screening of fully cured specimens, the basic recipe used should have been qualified for its overall tissue response by methods such as those suggested in Practice F 748 or ISO 10993 for the intended application, including testing according to Practice F 981.

[3] Withdrawn.
~~[4] Annual Book of ASTM Standards, Vol 15.09.~~
[4] Available from Association for Advancement of Medical Instrumentation, 1500 Wilson Blvd., Suite 417, Arlington, VA 22209.
~~[5] Discontinued; See 1997 *Annual Book of ASTM Standards* , Vol 08.01.~~
[5] Available from American National Standards Institute (ANSI), 25 W. 43rd St., 4th Floor, New York, NY 10036, http://www.ansi.org.